Development of [ 18F]FRP-170 injection for imaging hypoxia by PET

Yoichi Ishikawa; Yoshihito Funaki; Ren Iwata; Shozo Furumoto; Eiko Nakata; Yukitsuka Kudo; Tomohiro Kaneta; Takashi Hakamatsuka; Yoshihiro Takai; Shogo Yamada

Development of [ ¹⁸F]FRP-170 injection for imaging hypoxia by PET

Yoichi Ishikawa, Yoshihito Funaki, Ren Iwata, Shozo Furumoto, Eiko Nakata, Yukitsuka Kudo, Tomohiro Kaneta, Takashi Hakamatsuka, Yoshihiro Takai, Shogo Yamada

研究成果: Article › 査読

2 被引用数 (Scopus)

抄録

A novel [ ¹⁸F]FRP-170 injection for imaging hypoxia by PET was developed for clinical use. The preparation was based on the simple on-column basic-hydrolysis and the whole procedure was automated by detecting He flow change for transferring and evaporating liquids. [ ¹⁸F]FRP-170 was prepared in around 15-20% decay-corrected radiochemical yield within 60 min and stable in saline for more than 6 hr. Radiochemical purity was over 99% and specific activity at EOS was 40-60 GBq/μmol. The radiation-absorbed dose to the whole body was estimated to be 1.0 mSv/185 MBq. The [ ¹⁸F]FRP-170 injection proved to be suitable for clinical use without acute toxicity or mutagenicity.

本文言語	English
ページ（範囲）	1-10
ページ数	10
ジャーナル	Kakuigaku
巻	42
号	1
出版ステータス	Published - 2005 4月 22

ASJC Scopus subject areas

放射線学、核医学およびイメージング

他のファイルとリンク

引用スタイル

@article{f9bbb60d992340b58ec8f3551fea46e6,

title = "Development of [ 18F]FRP-170 injection for imaging hypoxia by PET",

abstract = "A novel [ 18F]FRP-170 injection for imaging hypoxia by PET was developed for clinical use. The preparation was based on the simple on-column basic-hydrolysis and the whole procedure was automated by detecting He flow change for transferring and evaporating liquids. [ 18F]FRP-170 was prepared in around 15-20% decay-corrected radiochemical yield within 60 min and stable in saline for more than 6 hr. Radiochemical purity was over 99% and specific activity at EOS was 40-60 GBq/μmol. The radiation-absorbed dose to the whole body was estimated to be 1.0 mSv/185 MBq. The [ 18F]FRP-170 injection proved to be suitable for clinical use without acute toxicity or mutagenicity.",

keywords = "Automated synthesis, F-18, FRP-170, Hypoxic cell maker, PET radiopharmaceutical",

author = "Yoichi Ishikawa and Yoshihito Funaki and Ren Iwata and Shozo Furumoto and Eiko Nakata and Yukitsuka Kudo and Tomohiro Kaneta and Takashi Hakamatsuka and Yoshihiro Takai and Shogo Yamada",

year = "2005",

month = apr,

day = "22",

language = "English",

volume = "42",

pages = "1--10",

journal = "Kakuigaku",

issn = "0022-7854",

publisher = "Japanese Society of Nuclear Medicine",

number = "1",

}

TY - JOUR

T1 - Development of [ 18F]FRP-170 injection for imaging hypoxia by PET

AU - Ishikawa, Yoichi

AU - Funaki, Yoshihito

AU - Iwata, Ren

AU - Furumoto, Shozo

AU - Nakata, Eiko

AU - Kudo, Yukitsuka

AU - Kaneta, Tomohiro

AU - Hakamatsuka, Takashi

AU - Takai, Yoshihiro

AU - Yamada, Shogo

PY - 2005/4/22

Y1 - 2005/4/22

N2 - A novel [ 18F]FRP-170 injection for imaging hypoxia by PET was developed for clinical use. The preparation was based on the simple on-column basic-hydrolysis and the whole procedure was automated by detecting He flow change for transferring and evaporating liquids. [ 18F]FRP-170 was prepared in around 15-20% decay-corrected radiochemical yield within 60 min and stable in saline for more than 6 hr. Radiochemical purity was over 99% and specific activity at EOS was 40-60 GBq/μmol. The radiation-absorbed dose to the whole body was estimated to be 1.0 mSv/185 MBq. The [ 18F]FRP-170 injection proved to be suitable for clinical use without acute toxicity or mutagenicity.

AB - A novel [ 18F]FRP-170 injection for imaging hypoxia by PET was developed for clinical use. The preparation was based on the simple on-column basic-hydrolysis and the whole procedure was automated by detecting He flow change for transferring and evaporating liquids. [ 18F]FRP-170 was prepared in around 15-20% decay-corrected radiochemical yield within 60 min and stable in saline for more than 6 hr. Radiochemical purity was over 99% and specific activity at EOS was 40-60 GBq/μmol. The radiation-absorbed dose to the whole body was estimated to be 1.0 mSv/185 MBq. The [ 18F]FRP-170 injection proved to be suitable for clinical use without acute toxicity or mutagenicity.

KW - Automated synthesis

KW - F-18

KW - FRP-170

KW - Hypoxic cell maker

KW - PET radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=20144389636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144389636&partnerID=8YFLogxK

M3 - Article

C2 - 15794116

AN - SCOPUS:20144389636

SN - 0022-7854

VL - 42

SP - 1

EP - 10

JO - Kakuigaku

JF - Kakuigaku

IS - 1

ER -

Development of [ 18F]FRP-170 injection for imaging hypoxia by PET

抄録

ASJC Scopus subject areas

他のファイルとリンク

フィンガープリント

引用スタイル

Development of [ ¹⁸F]FRP-170 injection for imaging hypoxia by PET